Press release from Companies

Publicerat: 2022-01-06 08:00:00

Cessatech A/S: Cessatech announces changes to the Board of Directors

Cessatech has appointed Rachel Curtis Gravesen as Observer to the Board of Directors with the intention that she will be proposed as a member of the Board of Directors at the Company’s Annual General Meeting, which is scheduled to be held on March 17, 2022. The appointment follows significant business progress over the last year and Ulla Buhl’s decision to resign as a member of the Board of Directors to focus on other activities.

Rachel has over 25 years’ experience in leadership, business and communication, with multiple roles in investor relations and communications. Currently running her own strategic investor relations and communications consultancy company working with biotechnology companies, Rachel also previously held roles at Genmab and Novo Nordisk as well as working as a journalist at CNBC Nordic and the BBC. 

Following today’s news, the Board of Directors will consist of Adam Steensberg (Chairman), Charlotte Videbæk, Martin Olin, Flemming Steen Jensen and Peter Birk with Rachel Curtis Gravesen assisting the Board of Directors in her capacity as Observer.

"Cessatech is entering a new and exciting period of growth and Rachel’s broad understanding of the international life sciences sector brings valuable experience to the Board of Directors," said Chairman of the Board of Directors Adam Steensberg. "I look forward to working with Rachel and wish to thank Ulla for her valuable contributions to the company during the last years.

For more information about Cessatech, please contact:
Jes Trygved, CEO
Phone: +45 9387 2309
E-mail: jes.trygved@cessatech.com

About Cessatech
Cessatech A/S is a Danish pharmaceutical company committed to developing and commercialising evidence-based and innovative medicines for children for the treatment of paediatric acute pain. Its lead asset (CT001) is an analgesic nasal spray for the treatment of acute and planned painful procedures in children. The advantages include needle-free administration, being easy to administer, a fast-acting therapeutic effect and being medically approved for children. 

Läs mer hos Cision
Läs mer om Cessatech A/S